Second-line HAIC yields higher response and longer PFS than TKIs in advanced HCC after immunotherapy failure

In advanced HCC after atezolizumab-bevacizumab failure, HAIC prolonged PFS vs TKIs (weighted median 7.1 vs 3.4 months, P<.001) and had higher response rate (35% vs 5%), with similar overall survival.

• After IPTW, HAIC's median PFS was 7.1 months vs 3.4 months for TKIs (P<.001).
• Objective response rate was 35% for HAIC vs 5% for TKIs (P=.002).
• Overall survival was similar (weighted median 10.5 vs 6.3 months, P=.32).

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.